All In Biotech

Drug Trial Radar · NCT05784441

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

A Phase 1b Multicenter, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

21

Actual

Start

Nov 6, 2023

Primary completion

Jan 6, 2027

Study completion Jan 3, 2040

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Mar 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long?

Conditions

  • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Interventions

  • JNJ-90009530Drug

    JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Calculate the Occurence of Adverse EventsTime frame: up to 24 months
  2. Determine Recommended Phase 2 dose (RP2D)Time frame: up to 24 months

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Iowa Hospital

    Iowa City, Iowa

  • University of Kentucky

    Lexington, Kentucky

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Rutgers University

    New Brunswick, New Jersey

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • Royal Prince Alfred Hospital

    Camperdown, Australia

  • Monash Medical Centre

    Clayton, Australia

  • Austin Hospital

    Heidelberg, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Australia

  • Westmead Hospital

    Westmead, Australia

  • Hadassah Medical Center

    Jerusalem, Israel

  • Sheba Medical Center

    Ramat Gan, Israel

  • University College London Hospitals

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.